Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.57 |
| ▸ | MMP13 | P45452 | 4/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038032 | 0.91 | TRPA1 (0.56) | TRPA1MMP13PTGER4SMN1; SMN2MAPT | |
| SCHEMBL6430172 | 0.91 | TRPA1 (0.48) | TRPA1MMP13SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL6728256 | 0.90 | TRPA1 (0.56) | TRPA1MMP13SMN1; SMN2MAPTNPSR1 | |
| SCHEMBL6728070 | 0.89 | TRPA1 (0.46) | TRPA1MMP13SMN1; SMN2MAPTPOLB | |
| SCHEMBL6462371 | 0.89 | MMP13 (0.52) | TRPA1MMP13PTGER4MAPTRXFP1 | |
| SCHEMBL6465573 | 0.88 | TRPA1 (0.46) | TRPA1MMP13SMN1; SMN2SLC22A8 | |
| SCHEMBL6257259 | 0.88 | TRPA1 (0.54) | TRPA1MAPTPOLBRXFP1CYP1A2 | |
| SCHEMBL6462194 | 0.87 | TRPA1 (0.43) | TRPA1MMP13PTGER4CYP1A2CYP2D6 | |
| SCHEMBL7032080 | 0.87 | CA2 (0.46) | TRPA1SMN1; SMN2POLB | |
| SCHEMBL6245168 | 0.86 | TRPA1 (0.62) | TRPA1SMN1; SMN2MAPTRXFP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | TRPA1 3888/4885MMP13 1/4885PTGER4 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.